DINESH

TTK Healthcare

Industry: Healthcare
Latest CMP 1,158
Today's Change ▲ 1.63%
52-Week High / Low 1,181 | 732
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 1,291
Expected Upside 5.6%
Forecast Horizon 2 Years
Historical CAGR 7.6%
1,000 Invested 15-Aug-2006
Today's Value 4,318
Investment Period 20 Years

Stock Snapshot

Post Results Return
+9.4%
Mild Positive Re-rating
1-Year Target Price
1,253
2-Year Target Price
1,291
52-Week High / Low
1,181 / 732
20-Day Return
+14.0%
Market Cap (Cr.)
1,636
Current PE
22.7
P/BV Ratio
1.5
Dividend Yield
0.8%
Industry PE
57.2

Price Performance

Basis of our Recommendation

TTK Healthcare's management has articulated a clear strategy focused on operational sustainability and innovation in high-value medical devices, which is expected to drive revenue growth and margin improvement. The company's commitment to integrating renewable energy and optimizing manufacturing processes reflects a proactive approach to cost management, enhancing its competitive position in a fragmented market. Vista's financial outlook anticipates stable revenue growth consistent with historical performance, supported by improving margins as operational efficiencies take hold. The healthcare sector's overall growth trajectory, bolstered by rising demand for organized tertiary care, aligns with TTK's strategic initiatives. However, the company must navigate regulatory challenges and potential margin pressures inherent in the industry. Over the next 12-24 months, key opportunities include advancements in medical device R&D and expansion in the Foods division, while watchpoints include regulatory compliance and the impact of macroeconomic factors on consumer spending. Overall, TTK Healthcare is positioned for steady growth, albeit with caution regarding external pressures that could affect profitability

👍 Why We Like This Stock

  • Management's focus on operational sustainability and high-value medical device innovation is expected to enhance revenue and margins
  • The integration of renewable energy and optimized manufacturing processes will likely improve cost resilience
  • Rising demand for organized tertiary care presents significant growth opportunities for TTK Healthcare

Things To Watch Out For

  • Regulatory compliance risks could pose challenges to operational execution and profitability
  • Margin pressures from competitive dynamics in the healthcare sector may impact earnings
  • Macroeconomic factors, such as inflation and consumer spending trends, could affect overall market conditions

Key Parameters

Balance Sheet Strength
Conservatively Financed
Market Share
Stable
Industry Outlook
Stable
Analyst View
Not Available
Dividend History
Consistent
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 753 801 857 918 965
Profit Before Tax (Cr.) 84 94 87 104 107
PBT Margin 11.2% 11.7% 1015.2% 11.3% 11.0%
Net Profit (Cr.) 62 72 64 77 79
Earnings Per Share 44.0 51.0 45.3 54.5 55.8

Analyst Recommendations

No analyst recommendations available.

Consensus Recommendation ► None
Consensus Target
Coverage 0 Analysts
Analysts' Viewpoint

Company Overview

Show Company Profile

TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.